Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Net sales	$ 18,219	$ 21,998	$ 34,508
Royalties	9,155,654	6,314,959	2,320,729
Licensing revenue	1,971,205	5,012,102	3,026,111
Consulting fees	0	46,667	280,000
Total revenues	11,145,078	11,395,726	5,661,348
Costs and expenses:
Research and development	1,249,755	972,078	1,223,931
General and administrative	4,774,828	5,231,881	6,470,449
Total costs and expenses	6,024,583	6,203,959	7,694,380
Operating income (loss)	5,120,495	5,191,767	(2,033,032)
Other income (expense):
Interest income	34,634	55,780	86,310
Other	0	15,823	13,130
Qualifying Therapeutic Discovery Grant	0	0	426,403
Total other income (expense)	34,634	71,603	525,843
Income (loss) before benefit (expense) for income tax	5,155,129	5,263,370	(1,507,189)
Income tax benefit (expense)	(2,174,054)	1,338,256	(1,351)
Net income (loss)	$ 2,981,075	$ 6,601,626	$ (1,508,540)
Basic net income (loss) per share (in dollars per share)	$ 0.47	$ 1.04	$ (0.24)
Diluted net income (loss) per share (in dollars per share)	$ 0.43	$ 0.95	$ (0.24)
Shares used in computation of basic net income (loss) per share (in shares)	6,351,245	6,340,648	6,261,214
Shares used in computation of diluted net income (loss) per share (in shares)	6,981,527	6,952,386	6,261,214